Last reviewed · How we verify
single dose Morphine
Morphine acts as a mu-opioid receptor agonist, producing analgesia by activating these receptors in the brain and spinal cord.
Morphine acts as a mu-opioid receptor agonist, producing analgesia by activating these receptors in the brain and spinal cord. Used for Pain management.
At a glance
| Generic name | single dose Morphine |
|---|---|
| Sponsor | Norwegian University of Science and Technology |
| Drug class | opioid |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Mechanism of action
Morphine's analgesic effects are primarily mediated through its binding to mu-opioid receptors, which are G protein-coupled receptors that inhibit the release of pain-producing neurotransmitters. This results in a decrease in the transmission of pain signals to the brain, leading to a reduction in perceived pain. Additionally, morphine can also produce respiratory depression, constipation, and other side effects due to its action on other opioid receptors and systems.
Approved indications
- Pain management
Common side effects
- Nausea
- Vomiting
- Constipation
- Dizziness
- Somnolence
Key clinical trials
- Analgesic Techniques for Robotic Prostatectomy Procedures (NA)
- Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty (PHASE4)
- Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults (PHASE3)
- Quality of Postoperative Analgesia and Functional Recovery After Elective Cesarean Delivery (NA)
- Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use (PHASE1)
- A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (PHASE1)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Ketamine Administration for Postoperative Pain Management in Patients Undergoing Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- single dose Morphine CI brief — competitive landscape report
- single dose Morphine updates RSS · CI watch RSS
- Norwegian University of Science and Technology portfolio CI